A Networking Resource for professionals
Welcome to Boston Events List
"Have you ever wondered what professional events are going on around the Greater Boston area? We list some of the important events for networking, technology training, entrepreneurial, product launches, conferences, trade-shows etc. The calendar includes events in life sciences, clean energy, technology, business, finance, legal, media etc that happen locally each week".
Boston Events List
follow us
Particulates in Biological products. Why test them and what are the new reporting requirements

Date Jan 31, 2012 10:00 AM Ending : Jan 31, 2012 11:30 AM
Event Type Life Sciences, Biotechnology,
Link to Website/Contact http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=701600?channel=BostonEL
Phone +1-650-620-3915
Location 2600 E. Bayshore Road Palo Alto California 94303
Organizer ComplianceOnline

Description:

The FDA has requested BLA sponsors to submit sub-visible particulate data for Well Characterized Protein Products in the clinical and commercial phases. The evidence continues to accumulate that particulates increase immunogenicity of the protein product. The regulatory requirements for testing Biologics for Particulates continue to evolve.

Why Should You Attend:

Proteinaceous Particulates in Biologics injectibles can arise from the aggregation of the protein product and can be induced by silicone droplets, metal particles and glass particles. Aggregates in protein products present a safety concern because they increase the immunogenicity of the product. The FDA has therefore requested BLA sponsors to present sub-visible particulate data at the clinical and commercial stage. The initially identified method –gap for suitable techniques for testing particles in the 0.2 - 10 micron range is being rapidly filled by new technologies.

Whether the aggregates found during in vitro testing truly reflects the quantity and type of aggregates in vivo is not clear and continues to be debated. Nevertheless this debate has increased the scrutiny of reviewers on the testing and reporting of particulates in Protein Therapeutics.

This updated webinar addresses recent discussions in the industry related to testing sub-visible particulates in Biologics injectibles. Recent FDA expectations for reporting data will be discussed. Methods for characterization and routine testing of particulates, their advantages and limitations will be discussed. Case studies where the various methods have been used for characterization of the sub-visible particles will be discussed.
Bookmark and Share Email
Actions Tags : protein therapeutics biological clinical stage biological commercial stage sub-visible particles
Back to Events List

 
   <     February 2012     >
SunMonTueWedThuFriSat
29 30 31 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 1 2 3
›› PyCon Rehearsals: Part 1
›› SharePoint Performance: Best Pra...
›› Ultra Light Startups Investor Fe...
›› NAAAP Boston 2012 Reveal Network...
›› Marketing/PR Wizards
Loading
Newsletter Subscription
Subscribe Unsubscribe